louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02350244: Active Prevention of MSDs (Musculoskeletal Disorders, Upper and Spine Members) in the Context of Computer Screen Work
Official title: Active Prevention of MSDs (Musculoskeletal Disorders, Upper and Spine Members) in the Context of Computer Screen Work
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Symptomatic Musculoskeletal Diseases
Latent Musculoskeletal Diseases
Keywords: musculoskeletal diseases
eyestrain
occupational diseases
computer work
muscle stretching exercise
computer software application
MSDs
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2015-01-29
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: Evaluate the benefit of an intervention by a computer program comprising active breaks, in the form of a personalized self-program on functional impairment and / or pain, among employees with latent or symptomatic upper extremity MSDs and spine (+/- eyestrain) in connection with the computer work environment.

Detailed description: The benefit of the intervention will be assessed among four groups of subjects: symptomatic and asymptomatic subjects randomized in control or experimental group.

Subjects of the experimental group will have to follow an intervention for one month, consisting in active breaks from computer work. Control group patients had no intervention.

Symptoms of MSD will be assessed via questionnaire before and after intervention, in all groups.

Eligibility criteria: Inclusion Criteria:

* - To carry out a professional activity.
* To be involved in a computer work for at least 5 hours a day.
* To be between 18 and 65 years.

Exclusion Criteria:

* - To be in sick leave.
* Rheumatic and neurological diseases which needed treatment.
* Workstations which have been recently changed.
* A behavioral and/or comprehension trouble

Primary outcomes:
measure: Nordic style questionnaire score
timeFrame: at 1 month
Secondary outcomes:
measure: Evolution of " Nordic style " and eyestrain questionnaires
timeFrame: at 1 month
measure: Evolution of global psychological status (HAD)
timeFrame: at 1 month
measure: Evolution of psychosocial work characteristics (VAS stress and satisfaction at work)
timeFrame: at 1 month
measure: Occurrence sick leave and frequency of work trips during the study.
timeFrame: at 1 month
measure: Adherence to the self-program
timeFrame: at 1 month
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU de Clermont-Ferrand
Study officials:
References:
citation: Lanhers C, Pereira B, Garde G, Maublant C, Dutheil F, Coudeyre E. Evaluation of 'I-Preventive': a digital preventive tool for musculoskeletal disorders in computer workers-a pilot cluster randomised trial. BMJ Open. 2016 Sep 22;6(9):e011304. doi: 10.1136/bmjopen-2016-011304.
Clinical trial NCT00261144: Collagenase in the Treatment of Cellulite
Official title: Collagenase in the Treatment of Cellulite
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Cellulite
Lead sponsor: Stony Brook University
Sponsor class: OTHER
First posted: 2005-12-02
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if collagenase injection will reduce or eliminate the appearance of cellulite of the thigh.

Detailed description: This is an open label study of collagenase injection therapy for reduction and/or elimination of cellulite of the posterolateral thighs.

Eligibility criteria: Inclusion Criteria:

* 10 x 10 cm area of cellulite of the posterolateral thigh(s)

Exclusion Criteria:

* any chronic, serious or uncontrolled medical condition
* inability to conform to study visits (12-15 per year)

Primary outcomes:
measure: Reduction and/or elimination of cellulite in the posterolateral thigh
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Stony Brook
country: United States
facility: Dept. Orthopaedics, SUNY Stony Brook
state: New York
Study officials:
affiliation: Dept. Orthopaedics, SUNY@Stony Brook, NY 11794
name: Marie A Badalamente, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Dept. Surgery, SUNY@Stony Brook, NY 11794
name: Alexander B Dagum, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05897944: Creating and Assessing a Voice Dataset for Automated Classification of Chronic Obstructive Pulmonary Disease
Official title: Creating and Assessing a Voice Dataset for Automated Classification of Chronic Obstructive Pulmonary Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: Automatic
Classification
COPD
Machine Learning
Mobile phone
Lead sponsor: Blekinge Institute of Technology
Sponsor class: OTHER
Collaborators: name: Excellence Center at Linköping - Lund in Information Technology (ELLIIT)
First posted: 2023-06-09
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Data will be collected from participants 18 years old and older with and without COPD diagnosis will be recruited.

Brief summary: This work aims to evaluate whether voice recordings collected from patients diagnosed with COPD and healthy control groups can be used to detect the disease using machine learning techniques.

Detailed description: Voice data and sociodemographic data on gender and age will be collected through the "VoiceDiganostic" application from the company Voice Diagnostic, which allows one to participate without location dependency. Participants with a diagnosis will be marked as the COPD group, and others will be marked as the healthy control group. Private information such as known comorbidities, personal security numbers, health parameters and communication information will be separately noticed in a participation table for each group.

The collected data will be transformed into mathematical vocal measures called voice features. A dataset consisting of voice features in conjunction with demographics and health data will be constructed for further usage as an input to ML techniques.

Descriptive statistical analysis will be held on attributes containing information on input data and gained outcomes from ML algorithms. The achieved results will be presented in the form of summary tables and graphs.

Eligibility criteria: Inclusion Criteria:

* being 18 years old and older.

Exclusion Criteria:

* being under 18 years old.

Primary outcomes:
measure: Accuracy
timeFrame: Week 51
measure: Input data importance scale
timeFrame: Week 51
Secondary outcomes:
Other outcomes:
Locations:
city: Karlskrona
country: Sweden
facility: Blekinge Institute of Technology
state: Blekinge
Study officials:
affiliation: Blekinge Institute of Technology
name: Johan Sanmartin Berglund, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03208244: DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant
Official title: Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Heart Transplant
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: End Stage Heart Disease
Hepatitis C
Keywords: Heart Disease
Heart Transplant
HCV
Hepatitis C
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2017-07-05
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Received heart transplant from HCV+ donor
Primary purpose: PREVENTION

Brief summary: This is a proof of concept, single center study for the donation of HCV-positive hearts to HCV negative recipient patients, with preemptive, interventional treatment with 12 weeks of commercially available DAA therapy to prevent HCV transmission upon transplantation.

Detailed description: The goal of this study is to determine if preoperative dosing and sustained administration of pan-genotypic DAA therapy after cardiac transplantation prevents the transmission of hepatitis C virus (HCV) infection from an HCV-positive donor heart to an HCV naïve recipient.

Eligibility criteria: Inclusion Criteria:

* Recipient is Age ≥ 18 years
* Serum ALT within normal limits with no history of liver disease
* Lack of sensitization (i.e. PRA \< 20%) that would be expected to result in a high likelihood of needing aggressive immunosuppression to treat rejection

Exclusion Criteria:

* Sensitization (i.e. PRA \>20%)
* Any liver disease in recipient
* Albumin \< 3g/dl or platelet count \< 75 x 103/mL
* Need for dual organ transplant

Primary outcomes:
measure: Number of Participants With Undetectable HCV RNA at 12 Weeks Post Treatment
timeFrame: 12 weeks post treatment
Secondary outcomes:
measure: Number of Participants With Adverse Events and Clinically Significant Out of Range Lab Values of DAA Therapy in Patients Undergoing Cardiac Transplantation
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Boston
country: United States
facility: Masschusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Raymond L Chung, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bethea ED, Gaj K, Gustafson JL, Axtell A, Lebeis T, Schoenike M, Turvey K, Coglianese E, Thomas S, Newton-Cheh C, Ibrahim N, Carlson W, Ho JE, Shah R, Nayor M, Gift T, Shao S, Dugal A, Markmann J, Elias N, Yeh H, Andersson K, Pratt D, Bhan I, Safa K, Fishman J, Kotton C, Myoung P, Villavicencio MA, D'Alessandro D, Chung RT, Lewis GD. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):771-780. doi: 10.1016/S2468-1253(19)30240-7. Epub 2019 Jul 26.
Clinical trial NCT01228344: Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria
Official title: Surveillance for the Effectiveness and Safety of Artemether-lumefantrine in Pediatric and Adult Patients With Malaria
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Malaria
Keywords: Artemether-lumefantrine
demographics
malaria
Lead sponsor: Novartis
Sponsor class: INDUSTRY
Collaborators: name: Centers for Disease Control and Prevention
First posted: 2010-10-26
Enrollment: 324
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any male or female infant, child or adult patient diagnosed with malaria who received artemether-lumefantrine and was reported to the Centers for Disease Control, Atlanta GA.

Brief summary: The purpose of this study is to describe the pediatric and adult patients (U.S. and foreign residents) diagnosed with malaria and treated with artemether-lumefantrine with regard to their demographics, including evaluation of their malaria immune status, treatment effectiveness, prior and concomitant medication use, and the occurrence of adverse events in association with artemether-lumefantrine treatment, based on the information collected in the CDC Malaria Case Surveillance Report Form.


Eligibility criteria: Inclusion Criteria:

* Any male or female infant, child or adult patient diagnosed with malaria who received artemether-lumefantrine and was reported to the CDC. Malaria may be clinically suspected or confirmed (microscopically, and/or by polymerase chain reaction \[PCR\], and/or rapid diagnostic test \[RDT\]).

Exclusion Criteria:

* NA

Primary outcomes:
measure: Effectiveness: Resolution of clinical signs and symptoms after artemether-lumefantrine treatment start
timeFrame: 4 weeks
Secondary outcomes:
measure: Adverse event, serious adverse event after artemether-lumefantrine treatment start
timeFrame: 4 weeks
measure: Pregnancies after artemether-lumefantrine treatment start
timeFrame: Up to delivery
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Centers for Disease Control and Prevention,GA
state: Georgia
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT06291844: Ocular Trauma and COVID-19 in Indonesia
Official title: Ocular Trauma During the COVID-19 Pandemic Era at an Indonesian Tertiary Care Center: A Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ophthalmological Disorder
Ocular Injury
COVID-19
Lead sponsor: Prof. R. D. Kandou General Hospital
Sponsor class: OTHER
First posted: 2024-03-04
Enrollment: 13
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Ocular trauma patients

Brief summary: Ocular injuries, a significant contributor to avoidable blindness globally, impact approximately 55 million individuals each year. Prompt initial treatment is vital for improving vision, yet the scarcity of skilled eye specialists often results in overcrowding at advanced medical centers. Moreover, the COVID-19 outbreak has introduced distinct factors into the management of ocular trauma. This research investigated the epidemiology of ocular injuries during the pandemic and offered observations on the distinctive hurdles and trends encountered.


Eligibility criteria: Inclusion Criteria:

* Ocular Trauma Patients presenting between January 2021 to March 2022

Exclusion Criteria:

* Presenting on days outside the inclusion criteria

Primary outcomes:
measure: Ocular Trauma
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Manado
country: Indonesia
facility: Department of Ophthalmology, Prof. R. D. Kandou General Hospital - Faculty of Medicine, Sam Ratulangi University
state: North Sulawesi
Study officials:
References:
Clinical trial NCT06804044: Intermittent Fasting (IF) Has Gained Recognition as a Promising Weight Loss Approach That Improves Body Weight, Insulin Resistance, and Metabolism. While Standard Diets Are Common in PCOS Management, IF May Address the Underlying Causes of Weight Gain and Offer Additional Metabolic Benefits
Official title: Effects of Different Dietary Programs on Anthropometric Parameters in Women With Polycystic Ovary Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Polycystic Ovary Syndrome
Weight Loss
Intermittent Fasting
Medical Nutrition Therapy
Caloric Restriction
Keywords: Diet
PCOS
IF
Lead sponsor: Bahçeşehir University
Sponsor class: OTHER
First posted: 2025-01-31
Enrollment: 33
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized controlled trial
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn if dietary interventions works to improve anthropometric measures in women with PCOS. The main questions it aims to answer are:

* Does intermittent fasting (IF) cause loss of body weight, fat and muscle mass?
* Can IF be considered more effective to medical and standart nutrition therapy (SDT)?
* What dietary problems do participants have when having IF diet?

Participants will:

* Follow IF, SDT, or no intervention for 8 weeks.
* Visit the clinic once every 2 weeks for check ups with a total of 5 visits for intervention groups IF and STD, visit at the beginning, second week and at the end for control group
* Keep dietary records

Detailed description: It was conducted in individuals who were diagnosed with PCOS as a result of clinical, biochemical and ultrasonographic medical evaluation by a gynecologist.

Eligibility criteria: Inclusion Criteria:

* Voluntariness to participate in the study
* BMI between 25-35 kg/m2
* Women between the ages of 18-45

Exclusion Criteria:

* An endocrine disorder other than polycystic ovary syndrome
* Chronic liver and kidney disease,
* Diabetes,
* Hypertension,
* Hyperuricemia,
* Heart Failure,
* Thyroid disease,
* Pregnant and breastfeeding women,
* Individuals with psychiatric disorders,
* Oncological diseases,
* Women using medication,
* Those with pacemakers and platinum,
* Those with special nutritional needs

Primary outcomes:
measure: Body Weight lose
timeFrame: 8 weeks
measure: Body Composition: Fat, Muscle
timeFrame: 8 weeks
measure: Body Circumference Measurements
timeFrame: 8 weeks
Secondary outcomes:
measure: Body Mass Indeks
timeFrame: 8 weeks
measure: Body Fat Ratio
timeFrame: 8 weeks
measure: Body Water
timeFrame: 8 weeks
measure: Dietary Energy Intakes
timeFrame: 8 weeks
measure: Energy Ratio from Macronutrients
timeFrame: 8 weeks
measure: Dietary Macronutrients Intakes
timeFrame: 8 weeks
measure: Dietary Micronutrients Intakes
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bahçeşehir University
state: Beşiktaş
Study officials:
References:
Clinical trial NCT02766244: Indocyanine Green (ICG) and SPY Imaging for Assessment of Burn Healing
Official title: Indocyanine Green (ICG) and SPY Imaging for Assessment of Burn Healing
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Burns
Lead sponsor: Texas Tech University Health Sciences Center
Sponsor class: OTHER
First posted: 2016-05-09
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Three patients were recruited for assessment of ICG fluorescence in burns.

Detailed description: The early determination of healing potential in indeterminate thickness burns may be difficult to establish by visual inspection alone, even for experienced burn practitioners. This case series explores the use of indocyanine green (ICG) fluorescence using portable bedside assessment as a potential tool for early determination of burn depth. Three subjects with indeterminate thickness burns had daily perfusion assessment using ICG fluorescence assessment using the SPY machine (SPY®, Lifecell Corp., NJ, USA) in addition to standard burn care. The fluorescence was quantified as a percentage of the perfusion of intact skin, and areas of hypo and hyper-perfusion were indicated. The burn surgeon, blinded to the ICG results, made a clinical determination of the need for skin grafting or discharge. The perfusion in areas of differing depth of burn were compared over the entire study period to determine both the magnitude of difference, and the point in the time course of healing when these changes became evident.

Eligibility criteria: Inclusion Criteria:

* patients with burn less than 15% TBSA

Exclusion Criteria:

* none

Primary outcomes:
measure: Perfusion of Burned Area
timeFrame: 5 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Dissanaike S, Abdul-Hamed S, Griswold JA. Variations in burn perfusion over time as measured by portable ICG fluorescence: A case series. Burns Trauma. 2014 Oct 25;2(4):201-5. doi: 10.4103/2321-3868.142397. eCollection 2014.
Clinical trial NCT05930444: Multimodal Machine Learning for Auxiliary Diagnosis of Eye Diseases
Official title: Multimodal Machine Learning for Auxiliary Diagnosis of Eye Diseases Using ChatGPT-based Natural Language Processing and Image Processing Techniques
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Eye Diseases
Lead sponsor: Eye & ENT Hospital of Fudan University
Sponsor class: OTHER
Collaborators: name: The Affiliated Eye Hospital of Nanjing Medical University
name: Suqian First Hospital
First posted: 2023-07-05
Enrollment: 9825
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The "normal participants" refers to individuals with no concerns or issues related to their eyes.

The "participants with eye-related chief complaints" refers to patients from various eye clinics across China. Each participant must undergo comprehensive medical tests and have their medical records reviewed for diagnosis.

Brief summary: With rapid advancements in natural language processing and image processing, there is a growing potential for intelligent diagnosis utilizing chatGPT trained through high-quality ophthalmic consultation. Furthermore, by incorporating patient selfies, eye examination photos, and other image analysis techniques, the diagnostic capabilities can be further enhanced. The multi-center study aims to develop an auxiliary diagnostic program for eye diseases using multimodal machine learning techniques and evaluate its diagnostic efficacy in real-world outpatient clinics.


Eligibility criteria: Inclusion Criteria:

* Informed consent obtained;
* Participants should be able to have Chinese as their mother tongue, and be sufficiently able to read, write and understand Chinese;
* For normal participants: individuals should have no concerns related to their eyes.
* For participants with eye-related chief complaints: individuals should have specific concerns or issues related to their eyes.

Exclusion Criteria:

* Incomplete clinical data to support final diagnosis;
* Patients who, in the opinion of the attending physician or clinical study staff, are too medically unstable to participate in the study safely.

Primary outcomes:
measure: Diagnostic accuracy of multimodal machine learning program
timeFrame: from July 2023 to March 2024
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: The Affiliated Eye Hospital of Nanjing Medical University
city: Shanghai
country: China
facility: Fudan Eye & ENT Hospital
city: Suqian
country: China
facility: Suqian First People's Hospital
Study officials:
References:
Clinical trial NCT02231944: An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients
Official title: An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Haemophilia B
Lead sponsor: Bio Products Laboratory
Sponsor class: OTHER
First posted: 2014-09-04
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To compare the first and second recovery assessments on Replenine®-VF and to evaluate recovery of different batches if patients changed batches during the study.

To evaluate Replenine®-VF in terms of long-term clinical efficacy, tolerance and safety


Eligibility criteria: Inclusion Criteria:

* Previously treated patients
* At least 12 years of age
* Severe Haemophilia B and without inhibitor to factor IX

Exclusion Criteria:

-

Primary outcomes:
measure: Recovery calculated from the first infusion of Replenine®-VF compared with that calculated 12 weeks later.
timeFrame: Baseline and 3 months post-baseline.
Secondary outcomes:
Other outcomes:
Locations:
city: Lodz
country: Poland
facility: Klinika Hematologii Instytutu Medycyny Wewnetrznej
city: Lublin
country: Poland
facility: Klinika Hematologii AM Lublin, ul.Jaczewskiego 8
city: Cambridge
country: United Kingdom
facility: Addenbrooke's Hospital, Hills Road
city: Cardiff
country: United Kingdom
facility: University Hospital of Wales, Heath Park
city: London
country: United Kingdom
facility: The Royal London Hospital
city: Manchester
country: United Kingdom
facility: Manchester Royal Infirmary, Oxford Road
city: Norwich
country: United Kingdom
facility: Norwich and Norfolk Hospital
Study officials:
References: